Galera Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024

AI Summary

Galera Therapeutics, Inc. (GRTX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Galera Therapeutics, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing details financial information and business operations for the first quarter of 2024. Key dates mentioned include various grant and plan effective dates dating back to 2018. The company's principal business address is located at 45 Liberty Blvd., Suite 230, Malvern, PA 19355. The filing is in accordance with the Securities Exchange Act of 1934.

Why It Matters

For investors and stakeholders tracking Galera Therapeutics, Inc., this filing contains several important signals. This 10-Q filing provides investors with crucial, up-to-date financial and operational information for Galera Therapeutics, Inc. for the first quarter of 2024, enabling informed investment decisions. The detailed financial disclosures within the 10-Q allow stakeholders to assess the company's performance, liquidity, and overall financial health, which is critical for a company in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — Galera Therapeutics, Inc. shows moderate risk based on this filing. The company operates in the pharmaceutical sector, which is subject to significant regulatory hurdles, clinical trial risks, and market competition, as indicated by the nature of its business and the typical risks associated with drug development.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-Q to understand Galera Therapeutics' current financial position and future prospects.

Key Numbers

• 2024-03-31 — Period of Report (10-Q filing)
• 2024-05-13 — Filed as of Date (10-Q filing)
• 2834 — Standard Industrial Classification (Pharmaceutical Preparations)
• 001-39114 — SEC File Number (10-Q filing)

Key Players & Entities

• Galera Therapeutics, Inc. (company) — Filer
• 2024-03-31 (date) — Period of Report
• 2024-05-13 (date) — Filed as of date
• 45 Liberty Blvd. (address) — Business Address
• Malvern (location) — Business Address City
• PA (location) — Business Address State
• 19355 (postal_code) — Business Address Zip
• 1934 Act (regulation) — SEC Act

FAQ

Industry Context

Galera Therapeutics operates within the pharmaceutical industry, focusing on the development of novel therapeutics. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and significant market competition.

Regulatory Implications

The company is subject to regulations from the U.S. Securities and Exchange Commission (SEC) for its public filings, such as this 10-Q. Additionally, as a pharmaceutical company, its operations are heavily regulated by bodies like the Food and Drug Administration (FDA) concerning drug development and approval.

What Investors Should Do

1. Review the financial statements for Q1 2024 to assess revenue, expenses, and cash flow.
2. Examine any disclosed risk factors to understand potential challenges and uncertainties.
3. Monitor future filings for updates on clinical trial progress and regulatory milestones.

Year-Over-Year Comparison

This filing is a 10-Q for the first quarter of 2024, providing an update from previous filings which would include annual reports (10-K) and potentially other quarterly reports.

Key Financial Figures

• $0.001 — e on which registered Common Stock, $0.001 par value per share GRTX The Nasdaq

Filing Documents

• grtx-20240331.htm (10-Q) — 987KB
• grtx-ex31_1.htm (EX-31.1) — 14KB
• grtx-ex31_2.htm (EX-31.2) — 16KB
• grtx-ex32_1.htm (EX-32.1) — 8KB
• grtx-ex32_2.htm (EX-32.2) — 7KB
• 0000950170-24-058197.txt ( ) — 4997KB
• grtx-20240331.xsd (EX-101.SCH) — 826KB
• grtx-20240331_htm.xml (XML) — 725KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Consolidated Balance Sheets 1 Consolidated Statements of Operations 2 Consolidated Statements of Comprehensive Loss 3 Consolidated Statements of Changes in Stockholders' Deficit 4 Consolidated Statements of Cash Flows 5 Notes to Unaudited Interim Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 26

Signatures

Signatures 27 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Quarterly Report, including without limitation statements regarding the impact of our discontinuation of the development of our product candidates; our plans to evaluate strategic alternatives; the sufficiency of our cash and cash equivalents and our ability to raise additional capital to fund our operations; and the plans and objectives of management for future operations, capital needs, and capital expenditures are forward-looking statements. The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected in the forward-looking statements, including, but not limited to, the following: our limited o

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements. GALERA THERAPEUTICS, INC. CONSOLIDATED BA LANCE SHEETS (IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS) (unaudited) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 13,466 $ 18,257 Prepaid expenses and other current assets 1,720 3,372 Total current assets 15,186 21,629 Property and equipment, net 62 71 Acquired intangible asset 2,258 2,258 Goodwill 881 881 Right-of-use lease assets 1,174 1,212 Other assets 90 90 Total assets $ 19,651 $ 26,141 Liabilities and stockholders' deficit Current liabilities: Accounts payable $ 1,046 $ 1,375 Accrued expenses 831 3,449 Lease liabilities 136 133 Total current liabilities 2,013 4,957 Royalty purchase liability 151,049 151,049 Lease liabilities, net of current portion 1,077 1,117 Deferred tax liability 203 203 Total liabilities 154,342 157,326 Stockholders' deficit: Preferred stock, $ 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding — — Common stock, $ 0.001 par value: 200,000,000 shares authorized; 54,392,170 shares issued and outstanding at March 31, 2024 and December 31, 2023 54 54 Additional paid-in capital 307,042 306,167 Accumulated deficit ( 441,787 ) ( 437,406 ) Total stockholders' deficit ( 134,691 ) ( 131,185 ) Total liabilities and stockholders' deficit $ 19,651 $ 26,141 See accompanying notes to unaudited interim consolidated financial statements. 1 GALERA THERAPEUTICS, INC. CONSOLIDATED STATEM ENTS OF OPERATIONS (IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS) (unaudited) Three months ended March 31, 2024 2023 Operating expenses: Research and development $ 1,488 $ 7,272 General and administrative 3,089 6,609 Loss from operations ( 4,577 ) ( 13,881 ) Other income (expenses): Interest inc

View Full Filing

View this 10-Q filing on SEC EDGAR